We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Membrane Metallo-Endopeptidase (MME) Antibodies|
|Conjugate||This MME antibody is un-conjugated Alternatives|
Immunohistochemistry (Formalin-fixed Sections) (IHC (f)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
|Supplier||Log in to see|
Product Details anti-MME AntibodyTarget Details MME Application Details Handling Images
|Purpose||This antibody is designed for the specific localization of human CD10 using IHC techniques in formalin-fixed, paraffin- embedded tissue sections. CD10 was identified initially as a common acute lymphoblastic leukemia specific antigen (CALLA). However, subsequent studies have shown that CD10 is expressed on the surface of a wide variety of normal and neoplastic cells. In malignant lymphomas, this antigen is expressed in lymphoblastic lymphomas, germinal center, Burkitt's lymphoma and in patients with chronic myeloid leukemia (CML). In addition, CD10 has been identified in the lymphoid progenitor cell surface, immature B cells in bone marrow of adult and germinal center B cells of lymphoid tissue. Also expressed in non-lymphoid cells and tissues such as breast myoepithelial cells, bile canaliculi, fibroblasts, and particularly high expression in the brush border of renal tubular cells and intestinal epithelial cells.|
|Characteristics||CD10 (CALLA, Common Acute Lymphoblastic Leukemia Antigen) is an integral Type II-membrane protein with a molecular weight of 100 kDa. CD10 was identified as a human membrane-associated neutral metalloendopeptidase. Synonyms are NEP, encephalokinase or neprilysin. CD10 is present on precursor B-cells, a subset of precursor T- cells, mature granulocytes, approximately 75 % of B-ALL, a subsetof T-ALL/T-LBL, and on all ALL-subtypes. Burkitt’s lymphomas and myelomas stain positive for CD10, as well as some diffuse large-cell B-cell lymphomas and most follicular lymphomas. Few tumours of epithelial origin like carcinomas of the kidney, bladder, prostate, uterus and liver stain also positive. MALT lymphomas and mantel cell lymphomas are negative for CD10. CD10 is a frequently utilised marker for differential diagnosis of lymphomas but is also used for discrimination of e.g. hepatocellular carcinomas vs. liver metastases of other origin. Immunohistochemistry (IHC) is a complex technique in which immunological and histological detection methods are combined. In general, the manipulation and processing of tissues before immunostaining, especially different types of tissue fixation and embedding, as well as the nature of the tissues themselves may cause inconsistent results (Nadji and Morales, 1983). Endogenous pseudoperoxidase and peroxidase activity or endogenous biotin and alkaline phosphatase activity can cause non-specific staining results depending on the detection system used. Tissues that contain Hepatitis B surface antigen (HBsAg) can produce false positives when using HRP detection systems (Omata et al, 1980). Insufficient contrast staining and/or improper mounting of the sample may influence the interpretation of results.|
|Purification||Ready-to-use, Prediluted, obtained from culture supernatant|
|Material not included||All reagents, materials, and laboratory equipment for IHC procedures are not provided with this antibody. This includes adhesive slides and cover slips, positive and negative control tissues, Xylene or adequate substitute, ethanol, distilled H2O, heat pretreatment equipment (pressure cooker, steamer, microwave), pipettes, Coplin jars, glass jars, moist chamber, histological baths, negative control reagents, counter-staining solution, mounting materials, and microscope.|
|Immunogen||Recombinant protein according to the external domain of human CD10.|
|Plasmids, Primers & others|
Target Details MMEProduct Details anti-MME Antibody Application Details Handling Images back to top
|Alternative Name||CD10 (MME Antibody Abstract)|
|Pathways||RTK Signaling, Peptide Hormone Metabolism, Regulation of Systemic Arterial Blood Pressure by Hormones, Smooth Muscle Cell Migration|
Application DetailsProduct Details anti-MME Antibody Target Details MME Handling Images back to top
Staining pattern: Cell membrane. The interpretation of the stain results is the full responsibility of the user. Any experimental result must be confirmed by a medically established diagnostic product or procedure.
Principles of the procedure: The demonstrations of antigens by IHC is a sequential procedure with several steps involving first the application of a specific antibody for the antigen of interest (primary antibody), then a secondary antibody which joins to the first, an enzyme complex, and the addition of a chromogenic substrate. The sample is washed between each step. Enzymatic activation of the chromogenic substrate creates a visible product where the antigen is located. The results are interpreted using a light microscope. The primary antibody can be used both in manual IHC and with automated immunostainers.
Paraffin-embedded tissue samples should be used. The antibody is also useful for immunostaining frozen tissue samples. Western blot techniques are not recommended.
Antigen retrieval: HIER Citrate Buffer pH 6.5
Working dilution: (only for concentrates) 1:25 – 1:200
Incubation: 30 min, RT
Control Tissue: Small intestine, kidney Anti-CD10 (
|Restrictions||For Research Use only|
HandlingProduct Details anti-MME Antibody Target Details MME Application Details Images back to top
|Buffer||The preparation contains saline buffer, stabilising and carriers proteins. (pH 7.4)|
|Precaution of Use||This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Storage Comment||Store at 2-8 °C until the expiration date printed on product label. Do not use after the expiration date. If fresh solutions are required, these must be prepared immediately prior to use, and will be stable for at least one day at room temperature (20-25°C). Unused portion of antibody preparation should be discarded after one day.If the product is stored under different conditions from those stipulated in these technical indications, the new conditions must be verified by the user. The validity period of the ready to use products when opened, is the same as the expiration date indicated on the label of intact product.|